FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022647282> ?p ?o ?g. }

• W2022647282 endingPage "322" @default.
• W2022647282 startingPage "317" @default.
• W2022647282 abstract "We previously demonstrated that delivery of a gene encoding an anti-erbB-2 intracellular single-chain antibody (sFv) resulted in down-regulation of cell surface erbB-2 levels and induction of apoptosis in erbB-2 overexpressing ovarian cancer cells. Based upon these findings, we hypothesized that human breast carcinomas overexpressing erbB-2 would be similarly affected by this genetic intervention. We evaluated the phenotypic effects resulting from intracellular expression of the anti-erbB-2 sFv on the human breast cancer cell lines MDA-MB-361, SK-BR-3, BT-474, MCF-7 and MDA-MB-231. Recombinant adenoviruses encoding either a reporter gene (AdCMVLacZ) or the endoplasmic reticulum (ER) directed anti-erbB-2 sFv (Ad21) were delivered to various breast cancer cell lines. Cell viability was determined by a proliferation assay and fluorescent microscopy allowed visualization of apoptotic cells. An erbB-2 ELISA quantified the endogenous erbB-2 levels of each cell line. The anti-erbB-2 sFv-encoding-adenovirus, Ad21, but not the β-galactosidase encoding adenovirus, AdCMVLacZ, was cytotoxic to >95% of the tumor cells in the MDA-MB-361 and SK-BR-3 lines, and >60% of the tumor cells in the BT-474 line. In marked contrast, the MCF-7 and MDA-MB-231 cell lines showed no change in the rate of cell proliferation following this treatment. The cytotoxic effects generated in the first three lines were a consequence of the induction of apoptosis by the anti-erbB-2 sFv. An ELISA specific for erbB-2 showed that the breast cancer cell lines most susceptible to the anti-erbB-2 sFv, MDA-MB-361, SK-BR-3 and BT-474, overexpressed the erbB-2 protein while the cell lines demonstrating no response to the anti-erbB-2 sFv, MCF-7 and MDA-MB-231, expressed the lowest levels of erbB-2. These results demonstrate that targeted killing of erbB-2 overexpressing cells via intracellular knockout can be accomplished in the context of breast carcinoma. Furthermore, erbB-2 levels in breast tumor cells may be predictive of their sensitivity to sFv-mediated killing. The ability to accomplish selective cytotoxicity of breast cancer cell lines overexpressing the erbB-2 tumor marker should allow for derivation of clinical gene therapy strategies for breast cancer utilizing this approach." @default.
• W2022647282 created "2016-06-24" @default.
• W2022647282 creator A5001093133 @default.
• W2022647282 creator A5005357486 @default.
• W2022647282 creator A5006078412 @default.
• W2022647282 creator A5013180976 @default.
• W2022647282 creator A5018144424 @default.
• W2022647282 creator A5063437113 @default.
• W2022647282 creator A5072380991 @default.
• W2022647282 date "1997-04-01" @default.
• W2022647282 modified "2023-09-26" @default.
• W2022647282 title "An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2" @default.
• W2022647282 cites W2123679993 @default.
• W2022647282 cites W2246949741 @default.
• W2022647282 doi "https://doi.org/10.1038/sj.gt.3300372" @default.
• W2022647282 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9176517" @default.
• W2022647282 hasPublicationYear "1997" @default.
• W2022647282 type Work @default.
• W2022647282 sameAs 2022647282 @default.
• W2022647282 citedByCount "50" @default.
• W2022647282 countsByYear W20226472822013 @default.
• W2022647282 countsByYear W20226472822015 @default.
• W2022647282 countsByYear W20226472822016 @default.
• W2022647282 crossrefType "journal-article" @default.
• W2022647282 hasAuthorship W2022647282A5001093133 @default.
• W2022647282 hasAuthorship W2022647282A5005357486 @default.
• W2022647282 hasAuthorship W2022647282A5006078412 @default.
• W2022647282 hasAuthorship W2022647282A5013180976 @default.
• W2022647282 hasAuthorship W2022647282A5018144424 @default.
• W2022647282 hasAuthorship W2022647282A5063437113 @default.
• W2022647282 hasAuthorship W2022647282A5072380991 @default.
• W2022647282 hasBestOaLocation W20226472821 @default.
• W2022647282 hasConcept C121608353 @default.
• W2022647282 hasConcept C153911025 @default.
• W2022647282 hasConcept C154317977 @default.
• W2022647282 hasConcept C202751555 @default.
• W2022647282 hasConcept C2779251935 @default.
• W2022647282 hasConcept C502942594 @default.
• W2022647282 hasConcept C54355233 @default.
• W2022647282 hasConcept C81885089 @default.
• W2022647282 hasConcept C86803240 @default.
• W2022647282 hasConceptScore W2022647282C121608353 @default.
• W2022647282 hasConceptScore W2022647282C153911025 @default.
• W2022647282 hasConceptScore W2022647282C154317977 @default.
• W2022647282 hasConceptScore W2022647282C202751555 @default.
• W2022647282 hasConceptScore W2022647282C2779251935 @default.
• W2022647282 hasConceptScore W2022647282C502942594 @default.
• W2022647282 hasConceptScore W2022647282C54355233 @default.
• W2022647282 hasConceptScore W2022647282C81885089 @default.
• W2022647282 hasConceptScore W2022647282C86803240 @default.
• W2022647282 hasIssue "4" @default.
• W2022647282 hasLocation W20226472821 @default.
• W2022647282 hasLocation W20226472822 @default.
• W2022647282 hasOpenAccess W2022647282 @default.
• W2022647282 hasPrimaryLocation W20226472821 @default.
• W2022647282 hasRelatedWork W187705992 @default.
• W2022647282 hasRelatedWork W1955444947 @default.
• W2022647282 hasRelatedWork W2010714957 @default.
• W2022647282 hasRelatedWork W2028322114 @default.
• W2022647282 hasRelatedWork W2048556400 @default.
• W2022647282 hasRelatedWork W2060509917 @default.
• W2022647282 hasRelatedWork W2109763600 @default.
• W2022647282 hasRelatedWork W2181893452 @default.
• W2022647282 hasRelatedWork W2291104341 @default.
• W2022647282 hasRelatedWork W4206956544 @default.
• W2022647282 hasVolume "4" @default.
• W2022647282 isParatext "false" @default.
• W2022647282 isRetracted "false" @default.
• W2022647282 magId "2022647282" @default.
• W2022647282 workType "article" @default.